Journal of Allergy and Clinical Immunology: Global (May 2023)
Facial redness in Japanese adolescents with atopic dermatitis treated with dupilumab: A case series
Abstract
This case series study is the first report of Japanese adolescents who experienced dupilumab facial redness after starting dupilumab treatment for refractory atopic dermatitis. In every case, dupilumab facial redness subsided without discontinuation of dupilumab within 3 months after onset.